HiC-COM: A 2-month intensive chemotherapy regimen for children with stage III and IV burkitt's lymphoma and b-cell acute lymphoblastic leukemia

Journal of Clinical Oncology

Volumn 9, Issue 1, 1991, Pages 133-138

  Schwenn, Molly R ^a,e   Blattner, Stephen R ^b   Lynch, Elizabeth ^c   Weinstein, Howard J ^d  

^a FLOATING HOSPITAL FOR CHILDREN   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d Maine Children's Cancer Program Portland   (United States)

^e TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; METHOTREXATE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; B CELL LEUKEMIA; BONE MARROW SUPPRESSION; BURKITT LYMPHOMA; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HUMAN; INFECTION; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MYELITIS; PRIORITY JOURNAL;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BURKITT LYMPHOMA; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; CYTARABINE; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMAN; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; METHOTREXATE; NEOPLASM STAGING; PILOT PROJECTS; REMISSION INDUCTION; SURVIVAL RATE; VINCRISTINE;

EID: 0026085776     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1991.9.1.133     Document Type: Article

References (24)

1. Ziegler JL: Treatment results of 54 American patients with Burkitt's lymphoma: A clinicopathologic study of 30 cases. I. Clinical factors relating to prolonged survival. Am J Med 58:314-321, 1975
2. Ramirez I, Sullivan MP, Wang Y, et al: Effective therapy for Burkitt's lymphoma: High-dose cyclophosphamide + high-dose methotrexate with coordinated intrathecal therapy. Cancer Chemothera Pharmacol 3:103-109, 1979
3. Brecher ML, Gardner R: Intensive chemotherapy for treatment of advanced Burkitt's lymphoma. Proc Am Soc Clin Oncol 22:406, 1981 (abstr)
4. Gasparini M, Lombardi F, Fossati-Bellani F, et al: Burkitt-type lymphoma (BL): Results of a prospective chemotherapy-radiotherapy program. Am Soc Clin Oncol 22:410, 1981 (abstr)
5. 2). N Engl J Med 308:559-565, 1983
6. Anderson JR, Jenkin RDT: N Engl J Med 309:311, 1983 (letter)
7. Schwenn M, Weinstein H, Nathan D, et al: High-dose methotrexate combination chemotherapy (M-BACOD) for advanced Burkitt's lymphoma: Failure to increase survival. Proc Am Soc Clin Oncol 2:73, 1983 (abstr)
8. Magrath IT, Janus C, Edwards BK, et al: An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults. Blood 63:1102-1111, 1984
9. Williams CKO, Folani AO, Seriki O: Patterns of treatment failure in Burkitt's lymphoma. Eur J Cancer Clin Oncol 19:741-746, 1983
10. Applebaum FR, Deisseroth AB, Graw RG, et al: Prolonged complete remission following high-dose chemotherapy of Burkitt's lymphoma in relapse. Cancer 41:1059-1063,1978
11. Philip T, Biron P, Herve P, et al: Massive BACT chemotherapy with autologous bone marrow transplantation in 17 cases of non-Hodgkin's malignant lymphoma with a very bad prognosis. Eur J Cancer Clin Oncol 19:1371-1379, 1983
12. Berard C, O'Conor GT, Thomas LB, et al: Histopathological definition of Burkitt's tumor. Bul WHO 40:601-607, 1969
13. Murphy SB: Management of childhood non-Hodgkin's lymphoma. Cancer Treat Rep 61:1161-1173, 1977
14. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, John Wiley, 1980
15. Mehta CR, Patel NR, Wei LJ: Computing exact significance tests with restricted randomizations rules. Biometrika 75:295-302, 1988
16. Murphy SB, Bowman WP, Abromowitch M, et al: Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J Clin Oncol 4:1732-1739, 1986
17. Patte C, Philip T, Rodary C, et al: Improved survival rate in children with stage III and IV B cell non-Hodgkin's lymphoma and leukemia using multi-agent chemotherapy: Results of a study of 114 children from the French pediatric oncology society. J Clin Oncol 4:1219-1226, 1986
18. Lazarus HM, Herzig RH, Herzig GP, et al: Central nervous system toxicity of high-dose systemic cytosine arabinoside. Cancer 48:2577-2582, 1981
19. Nand S, Messmare H, Patel R, et al: Neurotoxicity associated with systemic high-dose cytosine arabinoside. J Clin Oncol 4:571-575, 1986
20. Breuer AC, Pitman SW, Dawson DM, et al: Paraparesis following intrathecal cytosine arabinoside: A case report with neuropathologic findings. Cancer 40:2817-2822, 1977
21. Wolff L, Zighelboim J, Gale RP: Paraplegia following intrathecal cytosine arabinoside. Cancer 43:83-85, 1979
22. Dunton SF, Nitschke R, Spruce WE, et al: Progressive ascending paralysis following administration of intrathecal and intravenous cytosine arabinoside. Cancer 57:1083-1088, 1986
23. Sullivan MP, Ramirez I: Curability of Burkitt's lymphoma with high-dose cyclophosphamide - High-dose methotrexate therapy and intrathecal chemoprophylaxis. J Clin Oncol 3:627-636, 1985
24. Lemerle J: Treatment of B-cell non-Hodgkin's malignant lymphomas of childhood in Europe - Recent and ongoing studies, in Lenoir GM, O'Conor GT, Olweny CLM (eds): Burkitt's Lymphoma: A Human Cancer Model, Proceedings of a Symposium. Lyon, France, IARC, 1985